Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jan 20, 2023 8:38am
144 Views
Post# 35235157

The Branded Cattle/Catalyst That Never Gets Old

The Branded Cattle/Catalyst That Never Gets Old
Just Remember: Anyone wanting to keep track of how many shares of Algernon Pharmaceuticals have been diluted by Moreau - simply take the current outstanding shares and multiply it by 2 (Two). That is the complete representation of true shares issued when you factor in both the 2 to 1 & 100 to 1 Reverse Splits under Moreau's reign. Thus, Moreau has issued upwards of 500,000,000 shares (Five Hundred Million) to date, not including fire sale warrants. I think you still have an offering on the table in Canada to raise money for the "parent" company. You also have the Camouflaged Dilution Deal to raise 10M USD for the "subsidiary" company. When you put the two companies together with combined shares, Moreau will have diluted the entire company by 1,200,000,000 (One Billion Two Hundred Thousand) outstanding shares, not including fire sale warrants. ^That's the full picture you are facing moving forward, if not actually backwards <  > ?
 
 
<< Previous
Bullboard Posts
Next >>